Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Burkholderia pseudomallei Infections (Melioidosis) - Overview
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
Aradigm Corp (Ictive)
Entasis Therapeutics Holdings Inc
MerLion Pharmaceuticals Pte Ltd
Soligenix Inc
Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fifloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melioidosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGX-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
Featured News & Press Releases
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference
Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Fifloxacin against Biological Threat Agents
May 31, 2016: FDA Grants Soligenix “Fast Track” Desigtion for SGX943 for the Treatment of Melioidosis
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Aradigm Corp (Inactive), H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Entasis Therapeutics Holdings Inc, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2020
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2020